selected publications
- Leveraging BRG1 Driven Ferroptosis Resistance to Overcome Treatment Resistance. 2025 GET IT
-
Histone demethylase KDM2A is a selective vulnerability of cancers relying on alternative telomere maintenance.
Nature communications.
2023
Academic Article
GET IT
Times cited: 19 -
A FOXO1-dependent transcription network is a targetable vulnerability of mantle cell lymphomas.
The Journal of clinical investigation.
2022
Academic Article
GET IT
Times cited: 14 -
Caspase-8 Regulates the Antimyeloma Activity of Bortezomib and Lenalidomide.
The Journal of pharmacology and experimental therapeutics.
2021
Academic Article
GET IT
Times cited: 8 -
Caspase-8 Inhibition Prevents the Cleavage and Degradation of E3 Ligase Substrate Receptor Cereblon and Potentiates Its Biological Function.
Frontiers in cell and developmental biology.
2020
Academic Article
GET IT
Times cited: 5 - Cell Cycle Dysregulation in Mantle Cell Lymphoma: Genomics and Therapy. Hematology/oncology clinics of North America. 2020 Information Resource GET IT
- Targeting CDK4/6 in mantle cell lymphoma. Annals of lymphoma. 2020 Academic Article GET IT
-
A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma.
Leukemia & lymphoma.
2019
Academic Article
GET IT
Times cited: 11 -
A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma.
Blood.
2019
Academic Article
GET IT
Times cited: 69 -
A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2015
Academic Article
GET IT
Times cited: 46 -
Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Leukemia & lymphoma.
2015
Academic Article
GET IT
Times cited: 49 -
CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Cancer research.
2015
Academic Article
GET IT
Times cited: 52 -
Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma.
Cancer discovery.
2014
Academic Article
GET IT
Times cited: 247 -
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Cell cycle (Georgetown, Tex.).
2013
Academic Article
GET IT
Times cited: 70 -
Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Blood.
2012
Academic Article
GET IT
Times cited: 77 -
MAGE-A inhibits apoptosis in proliferating myeloma cells through repression of Bax and maintenance of survivin.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2011
Academic Article
GET IT
Times cited: 93 -
Noxa mediates p18INK4c cell-cycle control of homeostasis in B cells and plasma cell precursors.
Blood.
2010
Academic Article
GET IT
Times cited: 23 -
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Cancer research.
2008
Academic Article
GET IT
Times cited: 92 -
Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1.
Proceedings of the National Academy of Sciences of the United States of America.
2004
Academic Article
GET IT
Times cited: 52 -
Behavioral and neurochemical characterization of transgenic mice carrying the human presenilin-1 gene with or without the leucine-to-proline mutation at codon 235.
Experimental neurology.
2003
Academic Article
GET IT
Times cited: 30